top of page
  • LinkedIn
  • Facebook
  • Instagram
  • Twitter
  • YouTube

Results found for ""

  • Mosa Meat maintains momentum with Novel Food submission in Switzerland

    Mosa Meat has garnered significant attention recently, and this week is no exception as the cultivated meat company submits a request for novel food authorisation in Switzerland, following the submission of the first cultivated beef dossier to the European Union . This new application, supported by Bell Switzerland, focuses on cultivated fat as a key ingredient that can be blended with plant-based components to enhance the flavour and texture of products such as hamburgers and meatballs. The submission marks a significant step in Mosa Meat's strategy to introduce cultivated products to the market. According to CEO Maarten Bosch, the company has invested thousands of hours and extensive laboratory analysis into this dossier, reflecting its commitment to meeting the rigorous safety standards established by Swiss regulators. “We have developed a revolutionary food with our cultivated fat that unleashes the full flavour of beef," Bosch commented. "This innovation has the potential to take plant-based products to a new level by recreating the authentic sensory experience of meat." "By starting with cultivated fat, we are paving the way to bring our first burgers to market while staying true to our long-term vision. Our first products will combine cultivated and plant-based ingredients, leveraging our internal know-how,” Mosa Meat’s endeavours are indicative of a broader commitment to the European cellular agriculture ecosystem. The company collaborates with a diverse range of partners, including chefs, retailers, and both plant-based and conventional meat producers. Bell Food Group, which invested in Mosa Meat in 2018, plays a significant role on its board, highlighting the interconnectedness of traditional and innovative food sectors. The applications for market authorisation in both the European Union and Switzerland are critical steps towards the commercial launch of cultivated products. Both processes are anticipated to take approximately 18 months, following Mosa Meat's recent formal tastings of cultivated burgers in a controlled setting in the Netherlands. These tastings represent a pivotal moment in demonstrating the viability of cultivated meat to regulators and consumers alike. #MosaMeat #BellFoodGroup #NovelFoods #Switzerland #cultivatedfat

  • Opinion: Timing and transparency – Cultivated meat’s path to long-term success

    By prioritising quality, engaging consumers and leveraging lessons from plant-based foods, the cultivated meat industry has a unique opportunity to revolutionise the food system, addressing global health and sustainability challenges while building trust for long-term success. Suzi Gerber, executive director of the Association of Meat, Poultry and Seafood Innovation (AMPS), explores how the industry can navigate the road to consumer acceptance. The cultivated meat industry is advancing rapidly, but it must also cultivate consumer acceptance as this nascent sector and its products continue to evolve. Cultivated meat has enormous potential to transform how we eat, think about food, and improve human and planetary health. However, achieving ambitious goals requires patience, strategy and, above all, including consumers at every stage. By engaging consumers thoughtfully and learning from older alternative protein categories like plant-based foods, the cultivated meat industry can lay a foundation for stable, long-term acceptance. Lesson #1 Consumers judge novel foods quickly – Make that first bite count Food impressions tend to stick. For novel foods, initial exposures often come to represent entire categories. Consumers have deeply ingrained habits, making it challenging to adopt new foods. Cultivated meat, however, is not one thing; it is a range of methods, food types, structures, nutritional profiles and impacts, improving rapidly and frequently, much like plant-based foods. However, differences between products and their progression over time aren’t always obvious to consumers. Often, one experience represents the whole category. Unlike common consumer goods like cellphones, which consumers expect to improve over time, foods aren’t typically understood to be as iterative. The second wave of plant-based products experienced a surge in popularity, reminiscent of the 'Peak of Inflated Expectations' (Gartner Hype Cycle, bottom image ). Like that model, this was followed by strikingly waning enthusiasm. Misalignment between development timelines (Innovation R&D S-Curve, top image ) and the progression of consumer expectations has been observed to result in bottoming out. Rushing to market may thus not yield the most successful or enduring products, particularly for disruptive innovations that require generating consumer interest from scratch. The cultivated meat industry should prioritise functional quality over speed. Companies and investors who focus on delivering products that meet genuine consumer demands will likely achieve greater success. Bringing consumers in and keeping them apprised of product iteration could build better relationships and foster trust. Companies would be well-advised to resist the urge to rush products to market, and financial stakeholders should understand the greater risks of being too quick to launch. One potential solution could be to support research into whether tech-inspired strategies, such as 'versioning,' are viable for cultivated meat products. Versioning signals to consumers that the product will evolve. Imagine releases like 'Cultivated Salmon Sashimi 1.0' or 'Cell-Cultivated Chicken Strips – Generation 3'. This approach not only helps prime consumer expectations but also allows companies to debut products after significant advancements that would ideally include engagement with consumers with at-home adoption studies. Versioning also allows every release to be a point of excitement, and an opportunity to reset impressions, encouraging consumers to come along for the journey. Lesson #2 Consumer involvement builds loyalty and acceptance Success depends on including consumers in insights research and activating them as influencers throughout the development process. This could include beta launches or early access programmes targeting both powerful social and political brokers as well as communities. The industry should seek to understand how these foods fit, or could fit into daily life for consumers. Going beyond isolated sensory evaluation can foster genuine relationship building, instilling not only personal investment in the product’s evolution but also reassurance that needs and desires are met. Ideally, creating a community of supporters precedes market launch, and remains ongoing. Industry-wide efforts can promote cultivated meat through public tastings that link the technology to broader issues like food security, sustainability and ethics. Achieving this requires support from independent advocates and pre-competitive collaboration, which will need significant support from investors and foundations. Lesson #3 A blessing in disguise – Slow regulatory approvals as opportunities Approval of new cultivated meat products has been slow. While the US may be falling behind other countries, FDA indicated that new guidelines for industry have been drafted and will be published in 2025. For many companies, this slow approval timeline was seen as a crisis, and indeed some tragically ran out of time waiting. However, there could be a silver lining – for companies that remain, this time has been used to refine and optimise their technology. Subsequently, several breakthroughs in texture, scalability and cost have been made – all factors that will significantly enhance consumer acceptance and societal benefit. This extra time for refinement offers a golden opportunity to ensure that the first products to reach consumers are top-tier. Conversations with financial stakeholders should emphasise the importance of long-term planning and the unique nature of consumer food acceptance. By treating the slow and thorough FDA process as a strategic opportunity rather than a setback, companies can develop products that build strong, positive associations from the start and emphasise that the careful FDA process should serve increased consumer confidence. Lesson #4 Nutrition needs industry-academic collaboration While cultivated meat could potentially optimise the nutritional composition of meat, success will depend on consumer confidence in even factual claims. Nutrition extends beyond label details; it requires rigorous, peer-reviewed research and publicly published data to demonstrate outcomes. While not required for food businesses, cultivated meat has an opportunity to become a role model for a new and improved food system by demonstrating the greater downstream health and environmental outcomes that result from the iterative industry-level commitment to societal benefit. However, this requires public funding and research conducted by trusted academic institutions. By doing so, companies can prove the importance of these foods and position these novel foods as vanguards of better health, social responsibility and sustainability in the food system – the future that most people want for the food system. Charting a path forward The cultivated meat industry has an unprecedented opportunity to reshape the future of food. By learning from past challenges, improving transparency and prioritising consumer engagement, the industry can build products that resonate. A steady approach – focused on loyalty, research and trust – can introduce novel foods that win public support. With this foundation, cultivated meat can meet today’s urgent needs while preparing to tackle tomorrow’s challenges. #opinion #cultivatedmeat #AMPS #consumeracceptance

  • The C-Label: Paving the way for trust and transparency in cultivated meat

    As cultivated meat transforms the food industry with promises of sustainability and ethics, the introduction of the C-Label sets a new standard for transparency. Bridging the gap between innovation and consumer trust, this certification guides producers and consumers alike through the complexities of this groundbreaking category. The Cell Base spoke to Renato Pichler, V-Label founder, to find out more about the implications of this new labelling system. The emergence of cultivated meat has sparked a revolution in the food industry, promising a more sustainable, ethical and innovative approach to producing animal protein. As this new frontier rapidly advances, consumers and producers alike face a pressing challenge: how do we ensure transparency, trust and clarity for these groundbreaking products? This is where labelling plays a critical role. For over 25 years, the V-Label has been a global leader in certifying vegan and vegetarian products. With its distinctive mark recognised by millions, V-Label has bridged the gap between consumers’ expectations and producers’ commitments, fostering trust in plant-based foods. Building on this legacy, the C-Label emerges as a pioneering certification tailored to cultivated meat – a groundbreaking category that combines scientific innovation with ethical responsibility. The need for a dedicated label for cultivated meat stems from its unique position in the food ecosystem. Unlike traditional meat or plant-based alternatives, cultivated meat is grown directly from animal cells, circumventing the need for breeding or slaughter. While the technology offers profound benefits – such as reducing environmental impact, eliminating animal suffering and ensuring food safety – it also introduces complexities that demand clear communication. Consumers are eager to understand how these products are made, whether they align with their values, and how they compare to conventional options. The C-Label answers these questions by serving as a trusted guidepost. It assures consumers that certified products meet rigorous standards for sustainability, animal welfare, and innovation. From the exclusion of fetal bovine serum (FBS) in production to the use of stress-free cell sourcing methods, the C-Label criteria underscore a commitment to ethical practices and cutting-edge technology. By doing so, it not only empowers consumers but also helps producers differentiate their offerings in a competitive marketplace. Moreover, the introduction of the C-Label underscores the importance of evolving alongside consumer expectations. Just as the V-Label brought clarity to the vegan and vegetarian industry, the C-Label seeks to demystify cultivated meat, making it accessible and appealing to a broad audience. It represents a seamless extension of the values that have guided our work for decades: promoting animal welfare, fostering sustainability, and ensuring product integrity. As cultivated meat continues to capture the public imagination, the role of certification becomes even more critical. Labels like the C-Label provide the transparency necessary to build consumer confidence and accelerate adoption. They highlight the extraordinary efforts of producers who are pushing the boundaries of what’s possible, ensuring that their innovations are not only groundbreaking but also responsible and ethical. Here, we asked Renato a few questions about the new label and its implications for the cultivated meat sector. Could you share the main vision behind launching this label for cultivated products? What role do you hope it will play in shaping the industry? The production of cultured products is currently very controversial. There are some justified points of criticism. On the other hand, this new method of food production offers many advantages regarding animal welfare and environmental protection. With our new C-Label, we want to introduce an ethical standard so that consumers can choose products that are ethically recommended. Given that this is the first label of its kind, what prompted the timing of the launch? Why is now the right moment to introduce it? The first countries have already approved cultured meat, and the first products are now being introduced in the animal feed sector in Europe. The C-Label will thus help to build the market from the outset by providing consumers with guidance. What impact do you anticipate this label will have on industry transparency and traceability? How might it address key concerns within cellular agriculture? Technology is developing very quickly in this area. As a result, companies are also very keen to keep their production methods secret. It is therefore all the more important for consumers that there is an independent label that monitors production according to the points that are most important to consumers. How do you envision this label influencing the acceptance of cultivated products among industry stakeholders, consumers and regulatory bodies? The C-Label acts as an interface between producers and consumers. The C-Label guidelines address the main concerns of consumers. Insofar as the regulatory authorities issue regulations intended to protect consumers, it can also provide useful information here. Are there any specific consumer or market trends that inspired the development of this label? How will it meet these evolving demands? The disadvantages of conventional meat production are becoming increasingly well known. However, many consumers are still unsure about cultured meat. The C- Label is therefore intended to promote the switch from meat from abattoirs. Could you share any exclusive insights into the development process? Were there particular challenges or breakthroughs that shaped the label’s final form? The technologies for producing cultivated products are still in the midst of development. It is therefore a challenge to select the criteria for a label in such a way that they also make sense in the long term. In the early days, cultured meat was produced using fetal calf serum. This serum is produced by killing pregnant cows and extracting the blood of their unborn calves. Only when it became possible to completely avoid this serum in production was it also possible to introduce a label. Do you expect this label to become a benchmark or inspire similar standards across the cultivated sector? If so, which areas of the industry might be most influenced? The C-Label places high demands on producers. We use it to show what is already technologically possible today. As it is the first label of its kind, it is quite possible that other regulations will be based on it in the future. Are there any long-term goals tied to this label, such as fostering industry innovation, supporting partnerships, or advancing consumer education? The C-Label is also intended to stimulate discussion about the new cultivated products. We will also play an important role in consumer questions. #CLabel #cultivatedmeat #interview #ProVeg #labelling

  • The Cultivated B unveils AI-enhanced biosensors for advanced bioprocess monitoring

    The Cultivated B has launched a new line of multi-channel biosensors designed to enhance the monitoring of cell culture and fermentation processes in biomanufacturing. This technology integrates artificial intelligence (AI) with real-time data analytics, providing bioprocess engineers with tools to improve accuracy and decision-making in bioprocessing. The new biosensors aim to address significant challenges in bioprocess monitoring by offering continuous, high-resolution insights into cultivation dynamics. This capability allows operators to detect deviations early, thereby enhancing efficiency and reducing the risk of contamination associated with traditional manual sampling methods. By eliminating the need for physical probes, the technology ensures more consistent process conditions. Key features of the biosensor technology include the ability to tailor solutions for specific molecules within each bioprocess. The sensors exhibit exceptional sensitivity, capable of detecting concentrations below picomolar levels. This precision enables the measurement of a diverse range of chemicals and metabolites, such as glucose, amino acids and lactic acid, allowing scientists to decode bioprocess dynamics effectively and make real-time adjustments to protocols and control strategies. The integration of advanced AI algorithms further enhances the functionality of the biosensors. These algorithms continuously analyse data collected from the bioreactor, providing actionable insights and recommendations for optimising media formulations. This unique feature is expected to improve measurement reliability, optimise resource usage and accelerate the time-to-market for biomanufactured products. Hamid Noori, founder and CEO of The Cultivated B, said: “The release of highly advanced biosensors is another crucial step towards our vision of bringing complex biotechnology to everyday life". "Our sensor technology for bioreactors accelerates the learning curve of bioprocessing, ensuring high-quality output and exceptional product quality. I am confident this will empower industries to streamline workflows and enable scalable processes through enhanced automation.” The biosensors are designed to meet the stringent requirements of high-throughput bioprocessing across various applications, including pharmaceuticals, biologics, food and beverage biotechnology, waste upcycling, and alternative protein production. #TheCultivatedB #biomanufacturing #biotech #biosensors #AI

  • World’s first cultivated meat dog treat launches in UK retail

    Meatly , a cultivated meat firm based in the UK, has announced the launch of the world’s first cultivated meat dog treat, 'Chick Bites'. This product, created in collaboration with plant-based dog food brand The Pack, will be available in a limited release at Pets at Home locations, starting February 7 2025. This launch follows Meatly’s achievement in July 2024, when it became the UK’s first regulatory-approved supplier of cultivated meat. The introduction of Chick Bites marks a significant milestone, as it represents the first instance of cultivated meat being used in pet food available for commercial sale worldwide. Chick Bites combine cultivated Meatly Chicken with plant-based ingredients, offering a nutritious alternative to traditional dog treats. The product is designed to meet the growing consumer demand for sustainable and healthy pet food options, allowing pets to enjoy familiar flavours while promoting environmental responsibility. Last October, in our ‘Start-up Spotlight’ series, we spoke with Owen Ensor, founding CEO of Meatly, about their milestone achievement – securing 'Europe's first' approval to sell cell-based meat. Read more here . Meatly’s approach aims to provide a viable solution to the challenges associated with conventional meat production, which often involves significant resource usage and environmental impact. The production process for Meatly Chicken is notable for its efficiency. A single sample of cells taken from one chicken egg can yield enough cultivated meat to sustain pet food production indefinitely. This method not only ensures a consistent supply of high-quality protein but also addresses concerns related to animal welfare and sustainability. Pets at Home, a key investor in Meatly, is the first retailer globally to offer cultivated meat pet food, aligning with its commitment to reducing the carbon footprint of pet food products. The retailer’s chief operating officer, Anja Madsen, highlighted the importance of innovation in pet care, stating that this partnership reflects a forward-thinking approach to developing products that resonate with environmentally conscious consumers. Owen Ensor, Founding CEO of Meatly, expressed enthusiasm about the launch, describing it as a 'giant leap forward' in the cultivated meat sector. He noted that despite securing only 1% of total European cultivated meat investment, Meatly has established itself as a pioneer in the market, demonstrating the potential for efficient and cost-effective routes to commercialisation. Damien Clarkson, CEO and co-founder of The Pack, said: “We’re incredibly excited to introduce cultivated meat to the pet world. Just two years ago this felt like a moon shot." "Today we take off. It’s a giant leap forward – toward a significant market for meat which is healthy, sustainable and kind to our planet and other animals. We’re proud to work alongside fellow pioneers Pets at Home and The Pack for this momentous endeavour." He continued: "It’s also a day to celebrate our incredible team at Meatly. Despite only raising 1% of total European cultivated meat investment, we are the first company to sell cultivated meat in both the UK and EU". "And we’re just getting started. Next we’ll scale our production and make products more widely available to consumers.” #Meatly #petfood #cultivatedmeat #UK

  • Japanese consumers show strong interest in cultivated eel, survey reveals

    A recent survey conducted by cultured seafood innovator, Forsea, highlights a significant openness among Japanese consumers towards cultured eel alternatives. The survey indicates that 25% of respondents are eager to try cultured eel, regardless of price, signaling a potential shift in consumer behaviour amidst rising concerns over sustainability and food security. Japan is the world's largest consumer of freshwater eel ( Anguilla japonica ), accounting for nearly 50% of global consumption, with a market valued at approximately $10 billion. However, the country faces challenges due to dwindling wild eel populations and escalating prices, which have made this traditional delicacy increasingly inaccessible. In a previous survey, 23% of participants expressed a love for eel but cited high costs as a barrier to purchase. Furthermore, over a third of respondents voiced concerns regarding the ecological impact of overfishing, contributing to the species' endangered status. Conducted in January 2025, the online survey included 2,000 respondents, evenly distributed by gender and age. Key findings include: Awareness of cultured seafood: 35% of respondents reported familiarity with cell-based products, and a notable willingness to explore cultured eel options. Health and sustainability concerns: Nearly a third of participants cited health benefits as a motivator for trying cultured seafood, while a similar percentage expressed interest in its sustainability attributes. Taste and pricing: Taste and price emerged as critical factors influencing consumer acceptance of cultured seafood. Forsea's innovative organoid technology allows for the cultivation of eel meat that closely mimics the flavor, texture and nutritional profile of traditional eel. This method enables fish cells to assemble into three-dimensional tissue structures with minimal reliance on growth factors, thereby reducing the environmental strain associated with conventional eel farming. “The results of this survey were encouraging, as it indicates a readiness among Japanese consumers to explore innovative food options,” said Roee Nir, co-founder and CEO of Forsea. “Having scoured the market, we also discovered consumer types who are potential customers for our product, from the environmentally conscious young adult to the health-conscious homemaker, to the vegetarian-minded student or the tech-savvy businessperson seeking new experiences.” “Our cultured eel has received a lot of positive traction the global food scene, particularly among Japanese food manufacturers,” Nir added. “As cell-cultivated alternatives makes progress in attaining regulatory approval in Japan and following our organoid platform’s recent demonstration of its exceptional capacity for scaling and cost effectiveness, the stage is set for commercial production.” The survey results reveal a nuanced understanding of consumer preferences. Over 50% of respondents consume eel at least once a year, with 10% indulging regularly. Notably, 50% indicated a willingness to pay premium prices for high-quality eel products. In light of these findings, Nir noted,: “There is a sizable market of consumers who are compelled to forgo eel enjoyment due to its rarity and high cost. This presents an untapped opportunity for cultured eel products.” The survey aligns with findings from the Cellular Agriculture Institute of the Commons (CAIC), which reported a growing awareness of cell-based foods among the Japanese public. CAIC's Board chairman, Keisuke Igarashi, remarked on the potential for cultured foods to alleviate food security concerns while responding to consumer demand for sustainable options. #Japan #cultivatedeel #consumeracceptance #Forsea #survey

  • Pluri secures $3.5m investment to bolster growth in cell-based technology

    Israeli biotech firm Pluri has announced the successful completion of a $3.5 million private placement, further solidifying its financial position as a leading player in the cell-based biotechnology sector. This investment, from long-term shareholder Merchant Adventure Fund, follows a recent $6.5 million placement led by global investor Alejandro Weinstein, bringing total recent financings to $10 million. The transaction is expected to close on or around February 20 2025, pending customary closing conditions. Under the terms of the latest agreement, Pluri will issue 759,219 shares at a price of $4.61 per share, along with warrants for an additional 45,553 shares at an exercise price of $5.568. This influx of capital is designed to support Pluri's strategic initiatives as it seeks to expand its influence in the cell-based technology landscape, which spans pharmaceuticals, food technology and agriculture. The recent investments are seen as a strong endorsement of Pluri’s vision and operational strategy. Yaky Yanay, Pluri's CEO, remarked on the significance of this continued backing from a major shareholder, stating, "This additional investment reaffirms the strength of Pluri’s strategy and the trust of our long-term investors in our ability to execute". The funds will primarily be allocated to advancing Pluri's proprietary 3D cell expansion technology, which is designed to create scalable and cost-effective cell-based solutions. This technology positions Pluri to tackle various global challenges, including food scarcity and sustainability issues in agriculture. The demand for cell-based products is growing, driven by increasing consumer interest in sustainable and ethical food sources. As traditional animal agriculture faces scrutiny over environmental impact and ethical concerns, companies like Pluri are well-positioned to capitalise on this shift. The company's recent entry into discussions to acquire Kokomodo could potentially open avenues into the cacao market, further diversifying its portfolio. Pluri's recent funding rounds reflect a broader trend of investment in biotechnology, particularly in sectors focused on sustainable food production. As the company continues to innovate and scale its operations, it aims to redefine industry standards and meet the evolving demands of consumers and manufacturers alike. The investments also underscore the growing confidence among investors in the potential of cell-based technologies to revolutionise food manufacturing, offering alternatives that promise to be both environmentally sustainable and economically viable. About Pluri Pluri is a biotechnology firm specialising in cell-based solutions aimed at addressing critical issues in food security, health and sustainability. The company's patented 3D cell expansion system is designed for efficient mass production of cells, making it a key player in the regenerative medicine, food-tech, and ag-tech sectors. As Pluri advances its mission, it remains committed to fostering partnerships that leverage its technology across various industries, signalling a promising future for both the company and the broader cultivated food market. #Pluri #biotech #investment #Israel #agtech #foodtech #cultivatedfood

  • Stämm and SuperMeat forge partnership to advance cultivated meat biomanufacturing

    Stämm, a biopharmaceutical manufacturer based in Argentina, has announced a strategic collaboration with cultivated chicken producer SuperMeat to enhance biomanufacturing processes for cultivated meat. This partnership, supported by mutual investor Varana Capital, aims to benchmark and integrate Stämm’s continuous bioprocessing technology into SuperMeat's production framework. The collaboration will leverage Stämm's advanced Bioprocessor technology, which has demonstrated significant cost reductions and increased productivity in pharmaceutical applications. The Bioprocessor is an automated, continuous, bubble-free bioreactor designed to optimise muscle fibre growth and enhance the formation of adipocytes, crucial for developing whole-cut cultivated meat products. SuperMeat has recently achieved a milestone by lowering the cost of cultivated chicken production to $11.79 per pound, a critical threshold for market competitiveness. The partnership aims to further refine this process, potentially increasing product mass and improving the structural and flavour profiles of cultivated meat. A joint team from both companies will conduct a pilot program at SuperMeat's facility, focusing on the integration of Stämm's Bioprocessor into the existing production line. Yuyo Llamazares Vegh, CEO of Stämm, said: "In the coming months, a joint team will benchmark and evaluate how to integrate our Bioprocessor into SuperMeat's end-to-end production process. We are excited to see the results of this unique alliance." Ido Savir, CEO of SuperMeat, added: "This partnership demonstrates how complementary technologies can combine to drive progress in the cultivated meat industry. By uniting our technologies, we create a pathway to whole cut cultivated meat products that deliver superior quality and consumer appeal." Stämm's Bioprocessor technology The collaborative efforts will not only focus on product development but also on creating a scalable model for future production and economic viability. The alternative protein market is projected to reach up to $290 billion by 2035, according to a report by BCG and Blue Horizon. This growth presents substantial business opportunities for companies operating within the cultivated meat sector. Ezra Gardner, co-founder and CIO of Varana Capital, noted that Israel’s robust entrepreneurial environment makes it an ideal location for advancing innovations in alternative protein production. "Israel's exceptional entrepreneurial spirit and technological prowess make it an ideal investment destination for advancing the revolution in alternative protein production, both by introducing Stamm's biomanufacturing innovation into its ecosystem and by combining it with Supermeat's ingenuity," he commented. #Stamm #SuperMeat #Israel #Argentina #biomanufacturing #cultivatedmeat #chicken

  • Solar Foods appoints Rami Jokela as CEO

    Solar Foods, a Finnish innovator in sustainable protein production, has announced the appointment of Rami Jokela as its new chief executive officer, effective April 1 2025. This leadership change comes as the company transitions from its foundational technological development phase to a focus on global market expansion, particularly in the Health & Performance Nutrition sector. Jokela's appointment is seen as a critical step in Solar Foods' strategy to enhance its market presence and operational capacity. His initial priorities will include driving growth in the US, implementing a concept sales model, and increasing production capacity at the company's Factory 01. Additionally, he will oversee the phased investment plan for Factory 02, with the goal of achieving positive EBITDA during the strategic period. With a robust background in scaling international businesses, Jokela previously served as chief sales officer at Körber Group, where he successfully implemented a go-to-market strategy that significantly increased annual order intake. His experience also includes leading digitalisation efforts at ABB Group, where he developed smart marine operations and established a substantial business presence in China. Solar Foods is poised to capitalize on the growing demand for sustainable food solutions. The company’s flagship product, Solein, is a CO2-based protein alternative that promises to redefine food production by utilising resources more efficiently than traditional agriculture. This aligns with global trends favoring environmentally friendly and resource-efficient food sources. Over the past seven years, Solar Foods has made significant strides, including securing food permits for Solein in key markets and demonstrating the technology's readiness for large-scale production. The company was also admitted to trading on the Nasdaq Helsinki First North Growth Market in September 2024, enabling it to finance its ambitious growth strategy. Pasi Vainikka, Solar Foods' founding CEO, will remain with the company until the end of 2025 to ensure a smooth transition for Jokela. Vainikka said: As the first employee of Solar Foods, and one of the co-founders of this amazing growth story, I am naturally very proud of what we have accomplished together with the team so far. Bringing a new harvest to humankind is not a small feat. It’s a big deal.“ "It was obvious from the very beginning that we were working with a truly global opportunity. As a significant shareholder of Solar Foods, this leadership transition, together with the other recently announced management changes, demonstrates that we are fully committed to the swift execution of the strategy announced in late 2024." He continued: "Building on the strong foundation laid over the past seven years, the company is now, under Rami’s leadership, ready for a significant expansion – first in the United States and then in other markets around the World. Even beyond Earth”. With Jokela at the helm, Solar Foods' management team will include experienced leaders across various functions, such as finance, technology, operations, strategy and commercial development. This diverse team is expected to drive the company's growth and innovation efforts as it seeks to establish itself as a leader in sustainable protein production. "In Solar Foods, I see the same motivation and the same capacity for huge growth," Jokela enthused. "The company’s groundbreaking technology has the potential to make a significant impact globally, and therefore I look forward to working with the team accelerating Solar Foods’ growth and bringing its innovative solutions to the world.” #SolarFoods #protein #appointment

  • EU launches Biotech and Biomanufacturing Hub to enhance competitiveness for start-ups and SMEs

    The European Commission has officially launched a new Biotech and Biomanufacturing Hub aimed at supporting innovative companies, particularly start-ups and small to medium-sized enterprises (SMEs), in navigating the complexities of the EU market. This initiative seeks to bolster the competitiveness of biotech firms and facilitate their growth by providing essential resources and information on available support mechanisms. The Biotech and Biomanufacturing Hub is designed to be an accessible resource, offering guidance in multiple EU languages. Key features of the hub include: Funding opportunities: Detailed information on various EU funding sources tailored for biotech and biomanufacturing companies. Research infrastructure: Access to research facilities that can aid in research and development efforts within the sector. Scaling resources: Networks, pilot testing facilities, and market insights to assist businesses in scaling operations. Intellectual property guidance: Information on the intellectual property rights available to innovative companies. Regulatory processes: Clear explanations of the authorisation processes for new biotech products, including human and veterinary medicines and food ingredients, along with support for applicants navigating these processes. Compliance requirements: An overview of the regulations that companies must adhere to when developing and marketing biotech products in the EU. The hub will be hosted on the Commission's Your Europe portal, serving as an operational tool for easy access to relevant EU legislation, financing opportunities, and business support networks like the Enterprise Europe Network and the European Cluster Collaboration Platform. This launch of the hub is part of the Commission's broader strategy to enhance the biotechnology and biomanufacturing sectors in the EU, as outlined in a strategy document published in March 2024. The establishment of the hub is expected to streamline the scale-up process for biotech companies and simplify regulatory navigation. Stéphane Séjourné, executive vice president for prosperity and industrial strategy, said: "Biotechnology is a key driver of industrial innovation, competitiveness and productivity, while using fewer resources, producing less emissions and generating less waste. From advancing healthcare solutions to bio-based products in sectors such as chemicals, food, detergents, paper & pulp and textiles, biotech holds transformative potential for scaling up Europe’s industrial production and increasing prosperity." He continued: "The EU is set to create an optimal environment to support its scale-up, ensuring this critical sector thrives for the benefit of our citizens and industries alike. The hub is a practical tool that will support this." Olivér Várhelyi, commissioner for health and animal welfare, added that biotechnology plays a fundamental role in enhancing the EU's competitiveness and fostering innovation. He highlighted the potential of artificial intelligence to transform the sector, particularly in the development of life-saving therapies and personalised medicine. The development of the Biotech and Biomanufacturing hub will be supported by a dedicated taskforce of SME advisors from the Enterprise Europe Network. This collaborative effort aims to ensure that the hub remains a practical tool for companies seeking to navigate the EU landscape effectively. Impact on the food industry The hub is particularly significant for the food landscape, addressing critical areas such as food safety, feed safety, and consumer products. Companies developing innovative ingredients for food or feed, novel foods, genetically modified organisms (GMOs) or sustainable pesticides will benefit from a clearer understanding of EU requirements, which can aid in bringing safe, compliant products to market while meeting consumer expectations. Food improvement agents: The hub provides guidance on food additives, enzymes and flavourings, which are crucial for preserving, colouring and stabilising food products. Understanding the authorisation process for these agents is essential for compliance and market access. Feed additives: For companies producing feed additives, the hub outlines the necessary steps for demonstrating safety and efficacy, including the scientific evaluation process conducted by the European Food Safety Authority (EFSA). Novel foods: The hub clarifies the authorisation process for novel foods, ensuring that only safe products reach the market. Companies can use the Novel Food status Catalogue to determine if pre-market authorisation is required. GMOs: For businesses using GMOs, the hub details the dual authorisation process required for market access, highlighting the importance of compliance with both GMO and feed additive regulations. Pesticides: The hub also supports companies developing alternatives to synthetic pesticides, providing insights into the streamlined authorisation process for microbial and other innovative solutions. Impact on the cultivated food sector 1. Regulatory clarity and support Streamlined authorisation processes: The hub provides clear guidance on the regulatory requirements for cultivated foods, helping companies navigate the complex authorisation processes. This clarity can expedite the time to market for new products. R isk assessment framework: By leveraging the expertise of the EFSA, companies can better understand the safety assessments required for novel food products, ensuring compliance and consumer safety. 2. Access to funding and resources Financial support: The hub outlines various EU funding opportunities specifically aimed at supporting innovative food technologies, including cultivated food ventures. This financial backing is crucial for startups and SMEs looking to scale their operations. Research infrastructure: Access to EU research facilities can facilitate R&D efforts, enabling companies to refine their products and processes more efficiently. 3. Innovation in food production Encouragement of sustainable practices: The emphasis on biotechnology's role in sustainability aligns with the goals of cultivated food producers, who aim to reduce the environmental impact of traditional animal agriculture. The hub can provide insights into sustainable practices and technologies. Networking opportunities: The hub connects companies with networks, pilot facilities and market insights, fostering collaboration and innovation within the cultivated food sector. 4. Consumer acceptance and market readiness Consumer safety and expectations: By ensuring that cultivated and cell-based foods meet stringent EU safety standards, the hub can help build consumer trust and acceptance of these products in the market. Market insights: The hub offers valuable information about consumer trends and preferences, allowing companies to tailor their products to meet market demands effectively. 5. Intellectual property protection IP guidance: The hub provides information on intellectual property rights, which is crucial for cultivated food companies looking to protect their innovations and maintain a competitive edge in the market. 6. Addressing challenges in scaling Scaling support: The resources available through the hub can assist companies in overcoming common challenges associated with scaling up production, such as regulatory compliance, funding and access to technology. #EuropeanCommission #Europe #startups #SMEs #biotech #biomanufacturing #innovation #RandD

  • Agronomics' Liberation Labs secures $50.5m funding to advance biomanufacturing capacity

    Agronomics , a player in the clean food investment space, has announced that its portfolio company, Liberation Labs , has successfully closed a $50.5 million funding round. This includes a $31.5 million convertible note and $19 million in insider bridge notes raised throughout 2024, contributing to a total of $125.5 million in deployable capital for the company. The funding round attracted participation from notable investors, including NEOM Investment Fund, Siddhi Capital, and Meach Cove Capital. Agronomics itself has committed $7.4 million to this round, reinforcing its belief in Liberation Labs' potential to reshape the industrial biotechnology landscape. Liberation Labs aims to address capacity bottlenecks in the fermentation sector through its Bio3 platform – a purpose-built biomanufacturing facility currently under construction in Richmond, Indiana. The plant is designed to feature 600,000 litres of fermentation capacity and is expected to be operational by the end of 2025. The site was selected based on critical factors such as access to sugar inputs, labour availability, utility rates and the regulatory environment, along with government incentives. The facility also has the potential for future expansion, with plans to increase capacity by an additional 4 million litres. Notably, Liberation Labs has already secured Letters of Intent (LOIs) from several large companies for over 200% of the available capacity for the first five years of operation, indicating strong market demand for its services. In addition to private investment, Liberation Labs has received a $25 million loan guarantee from the US Department of Agriculture, aimed at supporting the completion of the biomanufacturing facility. This backing underscores the growing interest from both government and industry stakeholders in advancing biotechnology solutions that can enhance food production capabilities. Agronomics continues to express confidence in Liberation Labs, citing the increasing demand for diversified and secure supply chains from both governmental entities and large corporations. The company anticipates that Liberation Labs will achieve breakeven in its first year of operations, driven by the pressing need for fit-for-purpose biomanufacturing capacity. Agronomics has invested a total of $25.03 million in Liberation Labs, representing approximately 19.6% of Agronomics' last published Net Asset Value as of September 30, 2024. The current funding round, structured as a Convertible Loan Note, will convert into equity upon the next equity financing. Agronomics retains a 37.7% stake in Liberation Labs. Jim Mellon, executive chair of Agronomics, highlighted the strategic importance of this funding round, commenting: "Liberation Labs is developing state-of-the-art fermentation infrastructure to transform the world's existing fermentation capacity". He continued: "This novel approach has never previously been attempted. The completion of this significant funding raise showcases the consistent and growing demand from startups, large multinational corporations and governments alike and is testament to the strength of the team led by Mark Warner and their successful execution of the strategy." This initiative is positioned to meet the rising global demand for precision fermentation proteins, which are increasingly sought after in various sectors, including food and beverage. #Agronomics #LiberationLabs #precisionfermentation #biotechnology #biomanufacturing #US #funding

  • MyriaMeat achieves milestone in cultivated pork with functional muscle tissue

    MyriaMeat , a cultivated meat start-up based in Munich, has announced a groundbreaking development in the production of lab-grown pork. The company has successfully created pig muscle tissue from pluripotent stem cells that exhibits spontaneous contractions, marking the first instance of functional muscle tissue being developed outside of a living organism. This development underscores the potential for producing real pork entirely outside of living animals, positioning cultivated meat as a direct alternative to conventionally farmed pork rather than merely a substitute. MyriaMeat aims to replicate the characteristics of pork in a 1:1 ratio, which could enhance consumer acceptance, particularly among those hesitant to embrace plant-based alternatives. Founded in 2022 as a spin-off from research at the University of Göttingen, MyriaMeat is spearheaded by CEO Florian Hüttner and chief scientific officer Malte Tiburcy. Their focus on utilizing pluripotent stem cells differentiates them from other companies in the cultivated meat industry, which often rely on cell cultures to create meat-like products. “For the first time, an animal muscle – in this case from a pig – derived from pluripotent stem cells not only exhibits the properties of real tissue but also spontaneous contractions,” Tiburcy noted, highlighting the significance of this technology. This advancement could facilitate the scalability of cultivated pork production , making it a viable option within the broader meat market. The ability to produce functional muscle tissue may also pave the way for more complex meat products in the future. Cultured pork with natural contractility from pluripotent stem cells (© MyriaMeat GmbH) MyriaMeat is actively seeking partnerships with investors and stakeholders in the meat industry to further develop its technology. Hüttner emphasised the company’s intention to collaborate with existing meat producers rather than compete with them. “The meat industry has established sales structures, expertise, and political networks that are invaluable for integrating cultured meat into the market,” he added. The company’s collaborative approach aims to leverage these existing frameworks to facilitate the introduction of cultivated meat products, potentially benefiting both traditional agriculture and the emerging cultivated meat sector. In addition to sustainability, MyriaMeat’s cultivated pork could address several safety concerns associated with conventional meat production. The risk of diseases such as foot-and-mouth disease is significantly reduced in cultivated meat production, which operates in a controlled laboratory environment. Hüttner remarked: “Cultured meat not only provides an ethical and ecological solution but also minimises disease exposure without genetic manipulation”. #MyriaMeat #cultivatedpork #muscletissue #stemcells #innovation #Germany

Search Results

bottom of page